Cell-penetrating anti-DNA antibodies and uses thereof inhibit DNA repair

US10961301B2 · kind B2 · utility

Assignees

• Yale University · US
• The Regents of the University of California · US
• The United States Government represented by the Department of Veterans Affairs · US

Inventors

• James E. Hansen · Panama City, US
• Peter Glazer · Guilford, US
• Richard H. Weisbart · Rancho Santa Margarita, US
• Robert N. Nishimura · Rancho Santa Margarita, US
• Grace Chan · Geelong, AU

Key dates

• Filing date: Jun 6, 2017
• Grant date: Mar 30, 2021
• Expiry date: Oct 14, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/77
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Antibodies that penetrate cell nuclei and inhibit DNA repair or interfere with DNA metabolism are provided for treatment of cancer (both directly and by sensitizing cancer cells to DNA-damaging treatments) or inhibiting or preventing viral infection, proliferation or metabolism. The method involves treating cells with a composition containing cell-penetrating anti-DNA antibodies or derivatives thereof, alone or in combination with treatment that induces DNA damage such as DNA-damaging chemotherapy or radiation. The impact of the cell-penetrating anti-DNA antibodies or derivatives thereof is potentiated in cancer cells that are deficient in DNA repair, and the cell-penetrating anti-DNA antibodies or derivatives thereof are synthetically lethal to cancer cells with DNA repair deficiencies.